Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, COMFORT-I investigators

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Geyer HL, Dueck AC, Scherber RM, Mesa RA

Emerging drugs for the treatment of myelofibrosis.

Geyer HL, Mesa RA

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Geyer HL, Mesa RA

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Geyer HL, Mesa RA

Quality of life in MPN comes of age as a therapeutic target.

Scherber RM, Geyer HL, Mesa RA

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN